NEW YORK, April 30, 2019 /PRNewswire/ -- Hoth Therapeutics,
Inc. (Nasdaq: HOTH) a biopharmaceutical company focused on unique
targeted therapeutics for patients suffering from indications such
as atopic dermatitis–also known as eczema–as well
as dermatological and chronic wound disorders, today announced
that its Chief Executive Officer, Mr. Robb
Knie will be presenting on May 2,
2019 at the ThinkEquity Conference.
The ThinkEquity Conference is being held at The Mandarin
Oriental Hotel at 80 Columbus
Circle (at 60th St) in New York
City. The ThinkEquity Conference is an exclusive event
dedicated to connecting small and micro-cap companies with
high-level institutional and retail investors.
For additional information on the ThinkEquity conference please
visit https://www.think-equity.com/thinkequity-conference.
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc., a Nevada corporation, is a
biopharmaceutical company focused on unique targeted therapeutics
for patients suffering from indications such as atopic dermatitis,
also known as eczema. Hoth has exclusive worldwide rights to the
BioLexa Platform.
Forward Looking Statements
This press release includes "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements in this press release include, but
are not limited to, statements that relate to the advancement and
development of the BioLexa Platform, the commencement of clinical
trials, the availability of data from clinical trials and other
information that is not historical information. When used herein,
words such as "anticipate", "being", "will", "plan", "may",
"continue", and similar expressions are intended to identify
forward-looking statements. In addition, any statements or
information that refer to expectations, beliefs, plans,
projections, objectives, performance or other characterizations of
future events or circumstances, including any underlying
assumptions, are forward-looking. All forward-looking statements
are based upon Hoth's current expectations and various assumptions.
Hoth believes there is a reasonable basis for its expectations and
beliefs, but they are inherently uncertain. Hoth may not realize
its expectations, and its beliefs may not prove correct. Actual
results could differ materially from those described or implied by
such forward-looking statements as a result of various important
factors, including, without limitation, market conditions and the
factors described under the caption "Risk Factors" in Hoth's Form
10K for the period ending December 31, 2018, and Hoth's other
filings made with the Securities and Exchange Commission.
Consequently, forward-looking statements should be regarded solely
as Hoth's current plans, estimates and beliefs. Investors should
not place undue reliance on forward-looking statements. Hoth cannot
guarantee future results, events, levels of activity, performance
or achievements. Hoth does not undertake and specifically declines
any obligation to update, republish, or revise any forward-looking
statements to reflect new information, future events or
circumstances or to reflect the occurrences of unanticipated
events, except as may be required by law.
Contact
Investor Relations Contact:
Phone: (646) 756-2997
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-inc-to-present-at-the-thinkequity-conference-300840393.html
SOURCE Hoth Therapeutics, Inc.